On March 15, 2021 Seneca Therapeutics, Inc. ("STI"), a clinical-stage biopharmaceutical company dedicated to the development of targeted oncolytic immunotherapeutics based on Seneca Valley Virus (SVV-001) reported the acceptance of a late breaking SVV-001 abstract to the American Association for Cancer Research (AACR) (Free AACR Whitepaper) annual meeting (Press release, Seneca Therapeutics, MAR 15, 2021, View Source [SID1234576665]). The study titled "Oncolytic Seneca Valley Virus (SVV) overcomes resistance to checkpoint inhibitor therapies in neuroendocrine and melanoma murine models expressing the receptor for SVV", was accepted for the e poster session during the meeting. The details of the abstract viewing are below:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Abstract Control Number: 5232
Title: Oncolytic Seneca Valley Virus (SVV) overcomes resistance to checkpoint inhibitor therapies in neuroendocrine and melanoma murine models expressing the receptor for SVV
Session Type: E-Poster Session

Session Category: Clinical Research (Excluding Trials)
Session Title: Combination Immunotherapies